Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...



Jen Farmer

This email address is being protected from spambots. You need JavaScript enabled to view it.

Executive Director

Title Created Date Category
Part 2 of the Phase II MOXIe study (RTA 408 or omaveloxolone) Monday, August 28, 2017 Clinical Trials - Active - Enrollment Closed
Cerebral Abnormalities in Friedreich Ataxia: A Review Tuesday, August 22, 2017 Scientific News
Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich's Ataxia Tuesday, August 22, 2017 Scientific News
Selected missense mutations impair frataxin processing in Friedreich ataxia Thursday, August 17, 2017 Funded Research
FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia Monday, August 14, 2017 Scientific News
Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia Thursday, August 10, 2017 Funded Research
Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia Tuesday, August 8, 2017 Scientific News
Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia Thursday, August 3, 2017 Scientific News
Pharmacological therapeutics in Friedreich Ataxia: The present state Friday, July 21, 2017 Funded Research
Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model Friday, July 21, 2017 Funded Research


Event I.jpg